Filana Therapeutics Inc. (FLNA)
Filana Therapeutics Inc. (FLNA) Stock Price, Analysis & Data
| Bid | 1.02 |
| Market Cap | 45.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.28M |
| Beta | -0.69 |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 0.72 |
| P/S (ttm) | n/a |
| Earnings Date | Oct 29, 2026 |
| Ask | 0.96 |
| Volume | 155,303 |
| Avg. Volume (20D) | 355,701 |
| Open | 0.93 |
| Previous Close | 0.93 |
| Day's Range | 0.93 - 0.96 |
| 52-Week Range | 0.86 - 4.98 |
| Analyst | Strong Buy |
| Price Target | 6.5 (584.21%) |
| Dividends | n/a |
| Ex-Dividend Date | Dec 13, 2012 |
About FLNA
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly ...
Financial Performance
In 2025, Filana Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -90.97M, an increase of 273.73%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for FLNA stock is "Strong Buy". The 12-month stock price forecast is 6.5, which is upside of 584.21% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
